News

News and Press Releases
Research | Drug Pipeline | Medications FDA Accepts Vertex Application for Expansion of Trikafta to Include Children ages 6-11

Today, Vertex Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted its application to expand Trikafta® (elexacaftor/tezacaftor/ivacaftor) to include children ages 6-11 years old with cystic fibrosis who have at least one F508del or a mutation in the CFTR gene that is responsive based on in vitro data. The FDA has granted priority review of the application and has indicated that it will make a decision by June 8, 2021. 

| 2 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Has Awarded Up to $3M to Kinnear Pharmaceuticals for Anti-Infective

The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.

| 3 min read